InnoTherapy Inc (246960) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.004x

Based on the latest financial reports, InnoTherapy Inc (246960) has a cash flow conversion efficiency ratio of -0.004x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-107.41 Million ≈ $-72.79K USD) by net assets (₩24.57 Billion ≈ $16.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 246960 company net worth for the company's overall valuation and market capitalisation.

InnoTherapy Inc - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how InnoTherapy Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

InnoTherapy Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of InnoTherapy Inc ranked by their cash flow conversion efficiency. Explore InnoTherapy Inc earnings quality ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
ChowChow Cloud International Holdings Limited
NYSE MKT:CHOW
0.044x
Medifron DBT Co. Ltd
KQ:065650
-0.472x
Salutica Bhd
KLSE:0183
-0.102x
Adriatic Metals
LSE:ADT1
0.000x
Tira Austenite Tbk
JK:TIRA
0.003x
Vakif Menkul Kiymet Yatirim Ortakligi AS
IS:VKFYO
-0.031x
Smartiks Yazilim AS
IS:SMART
0.098x
Mg Internation
PA:ALMGI
-0.026x

Annual Cash Flow Conversion Efficiency for InnoTherapy Inc (2015–2024)

The table below shows the annual cash flow conversion efficiency of InnoTherapy Inc from 2015 to 2024. View InnoTherapy Inc (246960) stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩15.52 Billion
≈ $10.52 Million
₩-5.96 Billion
≈ $-4.04 Million
-0.384x -157.47%
2023-12-31 ₩18.90 Billion
≈ $12.81 Million
₩-2.82 Billion
≈ $-1.91 Million
-0.149x +52.60%
2022-12-31 ₩13.05 Billion
≈ $8.84 Million
₩-4.10 Billion
≈ $-2.78 Million
-0.315x +20.39%
2021-12-31 ₩10.08 Billion
≈ $6.83 Million
₩-3.98 Billion
≈ $-2.70 Million
-0.395x -78.14%
2020-12-31 ₩12.94 Billion
≈ $8.77 Million
₩-2.87 Billion
≈ $-1.95 Million
-0.222x -2.53%
2019-12-31 ₩15.08 Billion
≈ $10.22 Million
₩-3.26 Billion
≈ $-2.21 Million
-0.216x +5.49%
2018-12-31 ₩9.52 Billion
≈ $6.45 Million
₩-2.18 Billion
≈ $-1.48 Million
-0.229x +68.62%
2017-12-31 ₩3.10 Billion
≈ $2.10 Million
₩-2.26 Billion
≈ $-1.53 Million
-0.730x -294.88%
2016-12-31 ₩6.07 Billion
≈ $4.12 Million
₩-1.12 Billion
≈ $-760.70K
-0.185x -200.06%
2015-12-31 ₩-6.23 Billion
≈ $-4.22 Million
₩-1.15 Billion
≈ $-779.63K
0.185x --

About InnoTherapy Inc

KQ:246960 Korea Medical Devices
Market Cap
$13.44 Million
₩19.83 Billion KRW
Market Cap Rank
#26400 Global
#1995 in Korea
Share Price
₩2335.00
Change (1 day)
+3.32%
52-Week Range
₩1440.00 - ₩2970.00
All Time High
₩25350.00
About

SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasi… Read more